Altasciences CRO experts Chad Rathlef and Lisa Sanford

Altasciences’ Commitment to Bioanalytical Excellence


Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

We have been your trusted drug development research partner for over 30 years. We are committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.

We recently launched the Unveiling the Invisible video campaign to showcase how our bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of your innovative therapies.

​​

RELATED RESOURCES

Our bioanalytical team excels in comprehensive bioanalytical services, including assay and method development, molecular biology, mass spectrometry, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry services, and more, to support your journey from discovery through Phase IV.

Below are some resources that highlight our extensive knowledge, and wealth of bioanalytical experience.


Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

Greater Montréal, Québec, 11/13, 2024Altasciences, a trusted drug development research partner  for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.

For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Quebec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.

“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences. 

Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market. 

Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.

To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched their Unveiling the Invisible video campaign to showcase how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.

View the fascinating video series here.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.

Julie-Ann Cabana
Altasciences
jcabana@altasciences.com  
 

BioBuzz: Part One—Exploring Philadelphia's CDMOs

Discover the Dynamic Landscape of GLP-1 Drug Development


In this issue of The Altascientist, we explore the current and future development of GLP-1 receptor agonists (GLP-1 RAs), and the complexities involved in the early phases.

Topics covered include preclinical models, bioanalytical assays, clinical study design, manufacturing, and the expanding applications of GLP-1 drugs in treating various health conditions. Exclusive case studies are also presented.

Managing the Complexities of Glucagon-like Peptide-1 Receptor Agonist Drug Development

Questions about your drug development program? Speak with one of our experts.

Related resources that may interest you:

Qualification of a Veterinary Glucometer for Use in Yucatan Miniature Swine

Sensitive ASO Quantitation for Decentralized Trials


In this poster presentation, our scientific team demonstrates the promising future of blood microsampling in decentralized clinical trials to support the development of antisense therapeutic drugs.

Find out how they achieved precision, accuracy, and linearity within acceptance criteria with our sensitive and selective bioanalytical method for determining ASOs. Covering an analytical range of 0.50 – 500 ng/ml, they used dried blood micro-samples collected via the Capitainer® qDBS (10 µL), and analyzed them using hybridization LC-MS/MS.

You may also be interested in the following:


Going Above and Beyond to Exceed Your Expectations


In this new video, our clinical and manufacturing experts share how their teams collaborate and tailor solutions to meet your unique needs. They highlight real examples of going above and beyond by implementing innovative strategies to ensure your projects stay on track.

Start watching!

Examples of Clinic-CDMO Collaboration to Meet Your Needs

Looking for a more seamless drug development and manufacturing experience? Speak with one of our experts today.

Related resources that may interest you:


.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

A Scalable Solution for Solubility Challenges

Poorly soluble molecules comprise more than 70% to as much as 90%, as of 2024,1 of the


Driving Progress in Gene Therapy

Altasciences is a leader in nonclinical research, including gene therapy. In this video, our experts discuss the latest advancements and challenges in the field, while showcasing how our cutting-edge facilities are specifically tailored to support your innovative gene therapy projects.

Evolving Landscape of Gene Therapy Development

Want to learn more? Speak with one of our experts.

Related resources that may interest you:


Subscribe to